E
PNT

Ergoteles’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Ergoteles’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-19,400
Closed -$141K – 1673
2023
Q1 		$141K Buy
+19,400
New +$144K 0.01% 1067

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's PNT Position: Q2 2023 in Review

Ergoteles sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q2 2023, closing a stake of 19,400 shares — an estimated $141K sold.

Ergoteles first reported a position in PNT in Q1 2023 and held it in 1 quarter. The position peaked at $141K in Q1 2023. 130 funds tracked by Wall St. Rank hold PNT as of Q2 2023.

  • Ergoteles reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 19,400 POINT Biopharma Global Inc. Common Stock shares in Q2 2023, an estimated $141K.
  • Ergoteles first reported a position in POINT Biopharma Global Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Ergoteles's POINT Biopharma Global Inc. Common Stock position peaked at $141K in Q1 2023.
  • 130 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.